Oxazepam glucuronide is a major urinary metabolite of the benzodiazepine drug, oxazepam. Oxazepam, marketed as Alepam, Medopam, or Murelax®, has been used extensively since the 1960s for treatment of anxiety and insomnia and in the control of symptoms of alcohol withdrawal. This certified reference solution is suitable for GC/MS or LC/MS applications with oxazepam or oxazepam glucuronide such as urine drug testing, pain prescription monitoring, toxicology analysis, or forensic testing.
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Murelax is a registered trademark of Aspen Pharma Pty Ltd
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Journal of analytical toxicology, 32(7), 491-498 (2008-08-21)
A single method for confirmation and quantitation of a panel of commonly prescribed benzodiazepines and metabolites, alpha-hydroxyalprazolam, alpha-hydroxyethylflurazepam, alpha-hydroxytriazolam, alprazolam, desalkylflurazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam, clonazepam, and 7-aminoclonazepam, was developed for three specimen types, urine, serum/plasma, and meconium.
Clinical pharmacology and therapeutics, 35(2), 161-169 (1984-02-01)
Ten healthy subjects were fed three diets for 10 days each: a control diet, a cabbage and brussels sprouts--containing diet, and the control diet a second time. Oxazepam was taken on day 7 and acetaminophen on day 10 of each
1,4-Benzodiazepine anxiolytics such as diazepam and halazepam are converted in vivo to oxazepam, an active metabolite with a hydroxyl group at the asymmetric C3 position. D-glucuronic acid couples with the C3 hydroxyl group of oxazepam to form pharmacologically inactive diastereomeric
Drug metabolism and disposition: the biological fate of chemicals, 14(1), 41-45 (1986-01-01)
The metabolic fate of oxazepam in the rat is more complex than in larger animal species. Condensation of the diazepinyl ring and phase 1 transformations which lead presumedly via an epoxide to metabolites hydroxylated on the 5-phenyl moiety of oxazepam
British journal of clinical pharmacology, 20(3), 225-234 (1985-09-01)
Single dose pharmacokinetics of oxazepam, 30 mg, have been studied in six healthy male volunteers in the absence of diflunisal and during continuous treatment with diflunisal 500 mg twice daily. During diflunisal treatment, peak plasma concentration of oxazepam significantly decreased
